PRR4

Chr 12

proline rich 4

Also known as: LPRP, PROL4

This gene encodes a member of the proline-rich protein family that lacks a conserved repetitive domain. This protein may play a role in protective functions in the eye. Alternative splicing result in multiple transcript variants. Read-through transcription also exists between this gene and the upstream PRH1 (proline-rich protein HaeIII subfamily 1) gene. [provided by RefSeq, Feb 2011]

ResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProtEctodermal dysplasia-syndactyly syndrome 1
5
Active trials
6
Pubs (1 yr)
P/LP submissions
P/LP missense
1.72
LOEUF
DN
Mechanism· predicted
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.72LOEUF
pLI 0.044
Z-score 0.56
OE 0.66 (0.261.72)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
-0.14Z-score
OE missense 1.05 (0.871.27)
75 obs / 71.6 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.66 (0.261.72)
00.351.4
Missense OE?1.05 (0.871.27)
00.61.4
Synonymous OE?1.12
01.21.6
LoF obs/exp: 2 / 3.0Missense obs/exp: 75 / 71.6Syn Z: -0.48

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

PRR4 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

RECRUITING
NCT06311214Phase PHASE2National Cancer Institute (NCI)Started 2025-03-18
Biopsy ProcedureBiospecimen CollectionComputed Tomography
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

ACTIVE NOT RECRUITING
NCT04963153Phase PHASE1National Cancer Institute (NCI)Started 2022-07-07
Biospecimen CollectionBone ScanComputed Tomography
TNBC - Triple-Negative Breast CancerHR+ Breast Cancer

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

NOT YET RECRUITING
NCT07080619Phase PHASE2Tianjin ConjuStar Biologics Co., Ltd.Started 2025-09-20
SC-101
Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableUpper Tract Urothelial Cancer

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

RECRUITING
NCT06820255Phase PHASE4Fondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-01-07
Platinum + GemcitabineAvelumab first-line maintenanceNGS test for DDR alterations
Breast NeoplasmBreast CancerBreast Tumors

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

RECRUITING
NCT05582499Phase PHASE2Fudan UniversityStarted 2022-11-01
DalpiciclibPyrotinibSHR-A1811